100 related articles for article (PubMed ID: 25689225)
1. Safety, tolerability and pharmacokinetic properties of the novel triazene TriN 2755 in tumour bearing dogs - a phase I study
Athanasiadi I; Geigy C; Hilger RA; Meier V; Rohrer Bley C
Vet Comp Oncol; 2017 Mar; 15(1):94-104. PubMed ID: 25689225
[TBL] [Abstract][Full Text] [Related]
2. An open-label dose escalation study evaluating tolerability and safety of a single 5-days course of temozolomide in dogs with advanced cancer.
Marconato L; Rohrer Bley C; Leone VF; Finotello R
Vet Comp Oncol; 2020 Dec; 18(4):838-842. PubMed ID: 32510792
[TBL] [Abstract][Full Text] [Related]
3. Safety evaluation of combination carboplatin and toceranib phosphate (Palladia) in tumour-bearing dogs: A phase I dose finding study.
Wouda RM; Hocker SE; Higginbotham ML
Vet Comp Oncol; 2018 Mar; 16(1):E52-E60. PubMed ID: 28799187
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of satraplatin in dogs with spontaneously occurring malignant tumors.
Selting KA; Wang X; Gustafson DL; Henry CJ; Villamil JA; McCaw DL; Tate D; Beittenmiller M; Garnett C; Robertson JD
J Vet Intern Med; 2011; 25(4):909-15. PubMed ID: 21564292
[TBL] [Abstract][Full Text] [Related]
5. Phase I dose-finding study and a pharmacokinetic/pharmacodynamic analysis of the neutropenic response of intravenous diflomotecan in patients with advanced malignant tumours.
Trocòniz IF; Garrido MJ; Segura C; Cendrós JM; Principe P; Peraire C; Obach R
Cancer Chemother Pharmacol; 2006 Jun; 57(6):727-35. PubMed ID: 16261364
[TBL] [Abstract][Full Text] [Related]
6. Tolerability and pharmacokinetic profile of a novel benzene-poly-carboxylic acids complex with cis-diammineplatinum (II) dichloride in dogs with malignant mammary tumours.
Kristiansen VM; Dewi S; Horsberg TE; Jonasdottir TJ; Moe L; Berlinger B; Lindkaer-Jensen S; Larsen S
Vet Comp Oncol; 2017 Mar; 15(1):118-132. PubMed ID: 25764447
[TBL] [Abstract][Full Text] [Related]
7. An open-label, dose-escalating phase I study of elsamitrucin (SPI 28090) in treatment of malignant solid tumors in dogs.
Fiocchi SC; Selting KA; Rosenberg MP; Kolli P; Lenaz G; Henry C
J Vet Intern Med; 2011; 25(4):897-902. PubMed ID: 21736623
[TBL] [Abstract][Full Text] [Related]
8. Preclinical study of dolastatin-10 in dogs with spontaneous neoplasia.
Thamm DH; MacEwen EG; Phillips BS; Hershey AE; Burgess KM; Pettit GR; Vail DM
Cancer Chemother Pharmacol; 2002 Mar; 49(3):251-5. PubMed ID: 11935218
[TBL] [Abstract][Full Text] [Related]
9. Phase I dose-escalation study of nimustine in tumor-bearing dogs.
Takahashi M; Goto-Koshino Y; Fukushima K; Kanemoto H; Nakashima K; Fujino Y; Ohno K; Endo Y; Tsujimoto H
J Vet Med Sci; 2014 Jun; 76(6):895-9. PubMed ID: 24521794
[TBL] [Abstract][Full Text] [Related]
10. Prospective trial of metronomic chlorambucil chemotherapy in dogs with naturally occurring cancer.
Leach TN; Childress MO; Greene SN; Mohamed AS; Moore GE; Schrempp DR; Lahrman SR; Knapp DW
Vet Comp Oncol; 2012 Jun; 10(2):102-12. PubMed ID: 22236329
[TBL] [Abstract][Full Text] [Related]
11. Dose-Escalation and Pharmacokinetic Study Following a Single Dose of Oxaliplatin in Cancer-Bearing Dogs.
Klahn S; Dervisis N; Gustafson DL; Abbott J
J Am Anim Hosp Assoc; 2020; 56(4):206-214. PubMed ID: 32412339
[No Abstract] [Full Text] [Related]
12. Phase I and pharmacokinetic evaluation of the combination of orally administered docetaxel and cyclosporin A in tumor-bearing dogs.
McEntee MC; Rassnick KM; Lewis LD; Zgola MM; Beaulieu BB; Balkman CE; Page RL
Am J Vet Res; 2006 Jun; 67(6):1057-62. PubMed ID: 16740102
[TBL] [Abstract][Full Text] [Related]
13. Safety evaluation of combination CCNU and continuous toceranib phosphate (Palladia(®) ) in tumour-bearing dogs: a phase I dose-finding study.
Pan X; Tsimbas K; Kurzman ID; Vail DM
Vet Comp Oncol; 2016 Jun; 14(2):202-9. PubMed ID: 24735385
[TBL] [Abstract][Full Text] [Related]
14. A Comparative Oncology Study of Iniparib Defines Its Pharmacokinetic Profile and Biological Activity in a Naturally-Occurring Canine Cancer Model.
Saba C; Paoloni M; Mazcko C; Kisseberth W; Burton JH; Smith A; Wilson-Robles H; Allstadt S; Vail D; Henry C; Lana S; Ehrhart EJ; Charles B; Kent M; Lawrence J; Burgess K; Borgatti A; Suter S; Woods P; Gordon I; Vrignaud P; Khanna C; LeBlanc AK
PLoS One; 2016; 11(2):e0149194. PubMed ID: 26866698
[TBL] [Abstract][Full Text] [Related]
15. Phase I clinical trial of oral rosiglitazone in combination with intravenous carboplatin in cancer-bearing dogs.
Allstadt Frazier S; McKemie DS; Guerrero TA; LaChapelle H; Skorupski KA; Kass PH; Rodriguez CO
Vet Comp Oncol; 2014 Mar; 12(1):1-9. PubMed ID: 22364238
[TBL] [Abstract][Full Text] [Related]
16. Phase I study to determine the maximal tolerated dose and dose-limiting toxicities of orally administered idarubicin in dogs with lymphoma.
Vail DM; Husbands BD; Kamerling SG; Simpson H; Kurzman ID; McDonnell A
J Vet Intern Med; 2012; 26(3):608-13. PubMed ID: 22404399
[TBL] [Abstract][Full Text] [Related]
17. Phase I dose escalation and pharmacokinetic study of BI 2536, a novel Polo-like kinase 1 inhibitor, in patients with advanced solid tumors.
Mross K; Frost A; Steinbild S; Hedbom S; Rentschler J; Kaiser R; Rouyrre N; Trommeshauser D; Hoesl CE; Munzert G
J Clin Oncol; 2008 Dec; 26(34):5511-7. PubMed ID: 18955456
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and Toxicity of Sodium Selenite in the Treatment of Patients with Carcinoma in a Phase I Clinical Trial: The SECAR Study.
Brodin O; Eksborg S; Wallenberg M; Asker-Hagelberg C; Larsen EH; Mohlkert D; Lenneby-Helleday C; Jacobsson H; Linder S; Misra S; Björnstedt M
Nutrients; 2015 Jun; 7(6):4978-94. PubMed ID: 26102212
[TBL] [Abstract][Full Text] [Related]
19. Dose finding study of oral PSC 833 combined with weekly intravenous etoposide in children with relapsed or refractory solid tumours.
Pein F; Pinkerton R; Berthaud P; Pritchard-Jones K; Dick G; Vassal G
Eur J Cancer; 2007 Sep; 43(14):2074-81. PubMed ID: 17716890
[TBL] [Abstract][Full Text] [Related]
20. Phase I dose escalation of single-agent vinblastine in dogs.
Bailey DB; Rassnick KM; Kristal O; Chretin JD; Balkman CE
J Vet Intern Med; 2008; 22(6):1397-402. PubMed ID: 19000250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
